Market Overview

Why Eli Lilly's Stock Is Trading Higher Today


Eli Lilly (NYSE: LLY) shares are trading higher on Monday amid overall strength in the health care sector.

The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.

Eli Lilly shares were trading up 2.46% to $157.24 at time of publication on Monday. The stock has a 52-week high of $164.90 and a 52-week low of $101.36.

Related Links:

Eli Lilly Delays New Study Starts

Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance


Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: why it's movingHealth Care Movers Trading Ideas General